Overview
- Merck and Bio‑Techne announced a definitive agreement on June 25, 2026 for an all‑cash $73 per share deal that values Bio‑Techne at about $11.3 billion.
- Merck will fund the acquisition with existing cash and newly issued debt, and both companies expect to close the transaction by late 2026 or early 2027 pending regulatory clearance and a Bio‑Techne shareholder vote.
- Merck projects roughly €140 million in cost synergies to be realized by the third year after closing and says the deal will be immediately accretive to its EBITDA margins.
- Bio‑Techne supplies reagents, instruments and services including about 6,000 proteins and hundreds of thousands of antibodies plus technologies such as ProteinSimple and RNAscope that strengthen Merck’s spatial biology and diagnostics offerings.
- Investors lifted Bio‑Techne shares roughly 20% after the announcement, while analysts flagged valuation and integration risks to watch as Merck absorbs Bio‑Techne’s staff, manufacturing sites and customer channels.